Table 2.

Multiple cancer and bilateral breast cancer among unselected and familial breast cancer patients, by ATMex39 D1853N and ATMivs38(-8)T>C genotype

ATMex39 D1853N	total		DD		DN		NN		OR (95% CI)*	p
Unselected breast cancer patients	803		485		285		33
Bilateral	52	6.5%	37	7.6%	14	4.9%	1	3.0%	0.60 (0.32–1.11)	0.11
Unilateral	751	93.5%	448	92.4%	271	95.1%	32	97.0%
Multiple cancer	83	10.3%	51	10.5%	31	10.9%	1	3.0%	0.95 (0.60–1.52)	0.91
Breast cancer only	720	89.7%	434	89.5%	254	89.1%	32	97.0%
Familial breast cancer patients	778		469		276		33
Bilateral	86	11.1%	53	11.3%	30	10.9%	3	9.1%	0.94 (0.59–1.49)	0.82
Unilateral	692	88.9%	416	88.7%	246	89.1%	30	90.9%
Multiple cancer	89	11.4%	57	12.2%	29	10.5%	3	9.1%	0.84 (0.53–1.32)	0.49
Breast cancer only	689	88.6%	412	87.8%	247	89.5%	30	90.9%
									*DN+NN vs. DD
ATMivs38(-8)T>C	total		TT		TC		OR (95% CI)	p
Unselected breast cancer patients	818		769		49
Bilateral	49	6.0%	45	5.9%	4	8.2%	1.43 (0.49–4.15)	0.53
Unilateral	769	94.0%	724	94.1%	45	91.8%
Multiple cancer	80	9.8%	70	9.1%	10	20.4%	2.56 (1.23–5.35)	0.02
Breast cancer only	738	90.2%	699	90.1%	39	79.6%
Familial breast cancer patients	774		717		57
Bilateral	84	10.9%	78	10.9%	6	10.5%	0.96 (0.40–2.32)	1.0
Unilateral	690	89.1%	639	89.1%	51	89.5%
Multiple cancer	92	11.9%	85	11.9%	7	12.3%	1.04 (0.46–2.37)	0.83
Breast cancer only	682	88.1%	632	88.1%	50	87.7%